About 40% of at-risk patients with COPD did not receive maintenance therapy despite having frequent or severe exacerbations.
Two phase 3, randomized trials of inhaled treprostinil for idiopathic pulmonary fibrosis (IPF) were conducted on the basis of preclinical and clinical evidence of an antifibrotic mechanism.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results